Tremfya One-Press Approved for Plaque Psoriasis
February 27, 2019 – The U.S. FDA has approved a new dosage form for Tremfya® (guselkumab), manufactured by Janssen Pharmaceutical. The Tremfya One-Press Patient-Controlled Injector is indicated for use by adults who have moderate-to-severe plaque psoriasis.
According to a press release, the injector is designed to fit comfortably in the hand and deliver a controlled injection while hiding the needle from sight through the injection process. The hidden needle may help patients maintain medication adherence by helping to address fear of the needle itself. In a clinical study, patients scored Tremfya One-Press 9.18 out of 10 for “satisfaction with self-injection” and 9.24 out of 10 for “ease of use.”
A click indicates when administration of the drug with the One-Press device is complete, and a safety system protects the needle after use. Recommended maintenance dosing is 100mg via subcutaneous injection once every eight weeks.
Janssen launched the product upon approval; however, pricing is not yet available.